Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Sep 16 - Sep 21
and indicates very good penetration to the brain
PubMed PMID: 23802098
Chemical Name: 4-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-4
8 nM in isolated enzyme assay and 101 nM in human whole blood
Formula: C32H38N2O5
Canagliflozin - CAS# 842133-18-0 Catalog No.:M10730-10 and indicates very good penetrationCanagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the
US$ 19.15
US$ 24.95
US$ 57.53
US$ 29.95
US$ 159.90
US$ 67.12
US$ 39.95
US$ 47.93